Dorry Segev

I was interested to note as I opened up the paper that one of the authors is a friend of mine who is a transplant surgeon in New York and had previously been at Johns Hopkins University, very well known for his work in Increasing access for transplant to underserved populations.

That's Dr. Dori Segev, and he's one of the authors of this article entitled Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.

And this is published in Epidemiology and Genetics.

And it can be found in Obesity, which is a journal about obesity and its management.

Bob Montgomery's large program of HLA incompatible living donor kidney recipients, although there's a survival benefit to that type of transplant, it turns out there's a subset of those patients that also develop severe recurrent constellations of infections and opportunistic infections, aspergillus, endophthalmitis, nocardia, severe chronic norovirus, et cetera, et cetera.

And together with Jennifer Motter, Dori Segev, Alan Massey, and colleagues now all at NYU, we examined the risk factors for this, and we found that the intensity of desensitization was strongly associated with virtually all of the infections we looked at in total number of infections, which also is associated with prolonged hospitalization and death-censored graft loss.

And many of these patients were hypogammaglobulinemic.

On the far right-hand side, you see our Johns Hopkins case series of severe chronic norovirus, and we identified hypogammaglobulinemia, again, as a major determinant of length of symptoms in those cases.